Month: January 2015

Prezcobix and Evotaz: Two New HIV Fixed Dose Combinations Approved this Week

January 29, 2015 Janssen Therapeutics, Division of Janssen Products, LP (Janssen), today announced the U.S. Food and Drug Administration (FDA) has approved PREZCOBIX™ (darunavir 800 mg/cobicistat 150 mg) tablets, an HIV-1 protease inhibitor combined with a CYP3A4 inhibitor, for the treatment of human immunodeficiency virus (HIV-1) in combination with other antiretroviral agents for treatment-naive and …

Prezcobix and Evotaz: Two New HIV Fixed Dose Combinations Approved this Week Read More »

Scroll to Top